Q-omics provides the consensus-scored SLC41A3 profile across patient tissues and cancer cell-line models. SLC41A3 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SLC41A3 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, SLC41A3 RNA expression shows 18,464 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, COAD, and THYM as cancer lineages where SLC41A3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC41A3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC41A3 survival associations across molecular data types. SLC41A3 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC41A3 RNA expression–survival associations across cancer types. High SLC41A3 expression shows unfavorable associations in LIHC, READ and OV, but favorable associations in UVM, ACC and KIRC. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SLC41A3 RNA expression.
This table summarizes SLC41A3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for SLC41A3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC41A3 shows lower tumor expression in THCA, KICH, KIRC and UCEC and higher tumor expression in COAD and LIHC. The COAD box plot shows higher SLC41A3 RNA expression in tumor versus normal tissue (log2 FC = +1.032, t-test p < 0.001).
This table shows molecular features associated with SLC41A3 in patient tissues and cancer cell lines. In patient samples, SLC41A3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC41A3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and CNS.
